CWA Asset Management Group LLC Has $16.59 Million Stock Holdings in AbbVie Inc. $ABBV

CWA Asset Management Group LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 39.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,640 shares of the company’s stock after acquiring an additional 20,264 shares during the period. CWA Asset Management Group LLC’s holdings in AbbVie were worth $16,587,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of AbbVie in the second quarter valued at $4,288,200,000. Laurel Wealth Advisors LLC increased its holdings in AbbVie by 18,384.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after buying an additional 5,675,095 shares during the period. Assenagon Asset Management S.A. increased its holdings in AbbVie by 550.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after buying an additional 3,666,521 shares during the period. Vanguard Group Inc. raised its stake in shares of AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after buying an additional 3,380,842 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new position in shares of AbbVie during the 2nd quarter worth about $581,817,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ABBV shares. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. Raymond James Financial set a $256.00 price objective on AbbVie in a report on Monday, November 3rd. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday. DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a research report on Tuesday, November 4th. Finally, Morgan Stanley upped their price target on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Trading Up 0.3%

Shares of ABBV stock opened at $229.26 on Monday. The firm’s 50 day moving average is $226.69 and its 200-day moving average is $214.14. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a market capitalization of $405.19 billion, a price-to-earnings ratio of 173.68, a PEG ratio of 0.96 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. AbbVie’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.